icon-facebookicon-instagramicon-pinteresticon-soundcloudicon-twittericon-youtube
Below is a list of all AMaRC trials:
BelaCarD FOR RELAPSED REFRACTORY MULTIPLE MYELOMA (PHASE I/II)

A phase I/II single arm study of combination belantamab mafodotin, carfilzomib and dexamethasone in patients with early relapsed multiple myeloma.

Find out more
FRAIL-M FOR TRANSPLANT INELIGIBLE MYELOMA (PHASE I/II)

Frailty-stratified, randomised controlled Bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma (TI-NDMM) – the FRAIL-M study

Find out more
IRIL FOR TRANSPLANT INELIGIBLE MYELOMA (PHASE II)

A prospective Phase II study of Isatuximab Rescue for Inadequate response to Lenalidomide and Dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma (IRIL)

Find out more
VCD-D FOR TRANSPLANT INELIGIBLE MYELOMA (Phase II) **recruitment closed**

A randomized phase 2 study of bortezomib, cyclophosphamide and dexamethasone induction (VCD) compared with VCD and daratumumab induction followed by daratumumab maintenance (VCDD) for the initial treatment of transplant ineligible patients with multiple myeloma

Find out more
V-VCD FOR TRANSPLANT ELIGIBLE MYELOMA (PHASE II) **recruitment closed**

An exploratory study of Venetoclax in combination with Bortezomib-Cyclophosphamide-Dexamethasone (VCD) induction therapy in newly diagnosed transplant eligible (NDTE MM) multiple myeloma with proteomic correlative studies

Find out more
KappaMab FOR RELAPSED REFRACTORY MULTIPLE MYELOMA (Phase IIb) **recruitment closed**

A Phase IIb, open label, sequential cohort study comparing KappaMab alone to KappaMab in combination with lenalidomide and low dose dexamethasone (MRd) in Relapsed Refractory Multiple Myeloma

Find out more
ITD FOR RELAPSED REFRACTORY MULTIPLE MYELOMA (PHASE II) **recruitment closed**

A prospective, multi-centre, single arm, phase 2 assessment of the efficacy and safety of the combination of ixazomib, thalidomide and dexamethasone (ITD) for relapsed and/or refractory multiple myeloma after 1 to 3 prior lines of therapy.

Find out more

Get in contact

For further information about our clinical trials, please contact us.